| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790249 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
Combining prostate cancer vaccines with immune checkpoint inhibitors has great potential for improving clinical outcomes in prostate cancer. Such combination approaches may create and then recruit tumor-specific T cells to tumor while also increasing their effector function. Other emerging agents may also enhance immune-mediated tumor destruction.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jason M. M.D., James L. M.D., Ph.D., Ravi A. M.D.,